LCCC 1029: Multi-Center, Randomized, Placebo-Controlled Phase II Study of Regorafenib in Combination With FOLFIRI Versus Placebo With FOLFIRI as Second-Line Therapy in Patients With K-RAS or BRAF Mutant Metastatic Colorectal Cancer
Dr. Todd Moore
Men or women, ages 18 and older, diagnosed with metastatic colorectal cancer. For additional criteria, call the Research Coordinator or visit the study weblink.
UNC Lineberger Comprehensive Cancer Center
This randomized (2:1), multi-center, placebo-controlled, phase II efficacy study is designed to compare PFS between regorafenib + FOLFIRI chemotherapy (ARM A) versus placebo + FOLFIRI (ARM B) in patients with mCRC and KRAS or BRAF mutant disease previously treated with a FOLFOX regimen.